----item----
version: 1
id: {6E984D50-CFCC-4DC9-8D26-AD52D4E9AA80}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/01/30/FDA OKs 2 HIV drugs BMS Evotaz JJs Prezcobix
parent: {BCCFFBED-8CF5-4EB8-8FFF-BBD8EF95AF0D}
name: FDA OKs 2 HIV drugs BMS Evotaz JJs Prezcobix
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 18a1043b-7592-4564-b989-cf00f07ef184

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 50

FDA OK's 2 HIV drugs: BMS' Evotaz, J&J's Prezcobix
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 44

FDA OKs 2 HIV drugs BMS Evotaz JJs Prezcobix
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1277

<p>The FDA was on a roll on 29 January approving new combination treatments for HIV-1 infection, with Bristol-Myers Squibb&rsquo;s Evotaz (atazanavir/cobicistat) and Johnson & Johnson subsidiary Janssen's Prezcobix (darunavir/cobicistat) both winning the agency&rsquo;s nod</p><p>Evotaz is the first and only protease inhibitor pharmaco-enhanced by cobicistat that is supported by comparative Phase III clinical trial data and had virologic failure rates as low as 6% at 48 weeks, BMS noted.</p><p>The drug is approved combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. </p><p>Evotaz is co-formulated to be one pill, once-daily, combining the protease inhibitor atazanavir &ndash; a drug marketed by BMS as Reyataz (atazanavir 200mg/300mg) &ndash; and cobicistat, a pharmacokinetic enhancer marketed as Tybost by Gilead Sciences.</p><p>Prezcobix was approved for HIV-1 in combination with other antiretroviral agents for treatment-naive and treatment-experienced adults with no darunavir resistance-associated substitutions.</p><p>The drug is a once-daily, fixed-dose antiretroviral combination tablet containing 800mg of darunavir &ndash; marketed by Janssen as Prezista &ndash; and 150mg of Gilead's cobicistat.</p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 277

<p>The FDA was on a roll on 29 January approving new combination treatments for HIV-1 infection, with Bristol-Myers Squibb&rsquo;s Evotaz (atazanavir/cobicistat) and Johnson & Johnson subsidiary Janssen's Prezcobix (darunavir/cobicistat) both winning the agency&rsquo;s nod</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 44

FDA OKs 2 HIV drugs BMS Evotaz JJs Prezcobix
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150130T082745
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150130T082745
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150130T082745
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC027672
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 50

FDA OK's 2 HIV drugs: BMS' Evotaz, J&J's Prezcobix
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

356366
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042244Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

18a1043b-7592-4564-b989-cf00f07ef184
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042244Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
